Tumor and immune cell imaging based on PD-l1 expression

JP2025118743A5Pending Publication Date: 2026-01-21JOHNS HOPKINS UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025075768
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-06-14
Filing Date
2025-04-30
Publication Date
2026-01-21

Smart Images

  • Figure 00000062_0000
    Figure 00000062_0000
  • Figure 00000062_0001
    Figure 00000062_0001
  • Figure 00000062_0002
    Figure 00000062_0002
Patent Text Reader

Abstract

To provide a contrast agent for detecting Programmed Death Ligand 1 (PD-L1), which is expressed on the surface of cells in a subject and the like, with high sensitivity and which is cleared within a short period of time, as well as an imaging method for detecting PD-L1.SOLUTION: An imaging agent has a peptide residue that specifically binds to PD-L1, preferably represented by the following formula (I) [n is 0 or 1; L is a linker; Rpt is a reporting moiety represented by DOTAGA (1,4,7,10-tetraazacyclododecane) coordinated with a 64Cu radioactive metal].SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art